Aneurysm Study of Pipeline in an Observational Registry

NCT ID: NCT01557036

Last Updated: 2015-01-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to further expand the body of clinical knowledge in patients undergoing Pipeline Embolization Device (Pipeline or PED) placement for intracranial aneurysms (IAs or ICAs) according to Pipeline's labeled indication.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Aneurysm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aneurysms treated with Pipleline

Aneurysms treated with Pipleline. All patients independently treated according to the labeled indications for use with the Pipeline Embolization Device

Pipeline Embolization Device

Intervention Type DEVICE

Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pipeline Embolization Device

Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PED

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

(All sites, All countries)

1. At least 1 Pipeline placed for treatment of an ICA
2. Patient or patient's Legally Authorized Representative (LAR) has signed an IRB- or EC-approved informed consent form, if required
3. Patient is willing and able to comply with follow-up visits


4US) Subjects who are age 22 or higher 5US) IA of at least 10 mm in maximum dimension along the internal carotid artery between the petrous and superior hypophyseal segments


4C) In Canada, the Pipeline™ Embolization Device is intended for use with or without embolic coils for the treatment of complex intracranial aneurysms that are not amenable to treatment with surgical clipping.

5C) Canadian licensing/approval is limited to devices that are between 3.25 mm and 5.00 mm in diameter.


4F) Unruptured IA, saccular or fusiform with an aneurysm sac diameter \> 15mm and not treatable with other current therapies ( EVT with coils with or without assisting system (intracranial stent) or balloon remodeling, or surgery) due to its specific morphology.

5F) IA previously treated with unruptured recanalization of the aneurismal sac \> 7 mm, not treatable with conservative treatment.

Exclusion Criteria

1. Active bacterial infection
2. A patient in whom dual antiplatelet therapy (aspirin and clopidogrel) is contraindicated
3. A patient who has not received dual antiplatelet agents prior to the procedure
4. Pre-existing stent is in place in the parent artery at the target aneurysm location
5. Angiography demonstrates inappropriate anatomy, e.g., severe pre-or post-aneurysm narrowing
6. Acutely ruptured aneurysm, defined as rupture of the target aneurysm Each site should refer to their country specific Instructions for Use/Approval(France) to determine final eligibility into the ASPIRe Registry.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Neurovascular Clinical Affairs

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Barrow Neurosurgical Associates

Phoenix, Arizona, United States

Site Status

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Site Status

Radiology Imaging Associates / Colorado Neurological Institute

Englewood, Colorado, United States

Site Status

Mayo Clinic

Jacksonville, Florida, United States

Site Status

Neurointerventional Associates, P.A.

St. Petersburg, Florida, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Neurosurgical Associates at Central Baptist

Lexington, Kentucky, United States

Site Status

Norton Neuroscience Institute

Louisville, Kentucky, United States

Site Status

Abbott Northwestern Hospital/Consulting Radiologists

Minneapolis, Minnesota, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

St. Paul Radiology

Saint Paul, Minnesota, United States

Site Status

Washington University

St Louis, Missouri, United States

Site Status

University of Buffalo Neurosurgery, Buffalo General Hospital

Buffalo, New York, United States

Site Status

The State University of New York, Stony Brook

Stony Brook, New York, United States

Site Status

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

St. Luke's Episcopal Hospital

Houston, Texas, United States

Site Status

The Methodist Hospital

Houston, Texas, United States

Site Status

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Site Status

Medical College Of Wisconsin/Froedtert Hospital

Milwaukee, Wisconsin, United States

Site Status

Clínica La Sagrada Familia

Buenos Aires, , Argentina

Site Status

Universitair Ziekenhuis Gent

Ghent, , Belgium

Site Status

Royal University Hospital

Saskatoon, Saskatchewan, Canada

Site Status

Besançon University Hospital

Besançon, , France

Site Status

Hôpital Gui de Chauliac

Montpellier, , France

Site Status

Hôpital Maison Blanche - CHU

Reims, , France

Site Status

Alfried Krupp Krankenhaus

Essen, , Germany

Site Status

Klinikum Stuttgart

Stuttgart, , Germany

Site Status

Niguarda CA Granda Hospital of Milan

Milan, , Italy

Site Status

Fondazione Istituto Neurologico "Besta"

Milan, , Italy

Site Status

Ospedale San Giovanni Bosco ASL Napoli 1 Centro

Napoli, , Italy

Site Status

University Hospitals of Geneva (HUG)

Geneva, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Belgium Canada France Germany Italy Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PED002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.